Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Diagnosis of AD

• Age 50-85

• MMSE 14-26

• Other Inclusion Criteria Apply

Exclusion Criteria:

• Significant Neurological Disease

• Major Psychiatric Disorder

• Clinically Significant Systemic Illness

• Other Exclusion Criteria Apply